[go: up one dir, main page]

AU2002220460A1 - The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits - Google Patents

The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits

Info

Publication number
AU2002220460A1
AU2002220460A1 AU2002220460A AU2046002A AU2002220460A1 AU 2002220460 A1 AU2002220460 A1 AU 2002220460A1 AU 2002220460 A AU2002220460 A AU 2002220460A AU 2046002 A AU2046002 A AU 2046002A AU 2002220460 A1 AU2002220460 A1 AU 2002220460A1
Authority
AU
Australia
Prior art keywords
fragments
hepatitis
virus
vaccine composition
diagnostic kits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220460A
Inventor
Shengxiang Ge
Ying Gu
Zhigiang He
Shaowei Li
Ningshao Xia
Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Sheng Tang Co Ltd
Original Assignee
Yang Sheng Tang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd filed Critical Yang Sheng Tang Co Ltd
Publication of AU2002220460A1 publication Critical patent/AU2002220460A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002220460A 2000-09-30 2001-09-30 The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits Abandoned AU2002220460A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN00130634A CN1345775A (en) 2000-09-30 2000-09-30 Polypeptide for preventing, diagnosis and treating hepatitis E virus and used as diagnostic reagent and vaccine
CN00130634 2000-09-30
PCT/CN2001/001469 WO2002040681A1 (en) 2000-09-30 2001-09-30 The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits

Publications (1)

Publication Number Publication Date
AU2002220460A1 true AU2002220460A1 (en) 2002-05-27

Family

ID=4594225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220460A Abandoned AU2002220460A1 (en) 2000-09-30 2001-09-30 The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits

Country Status (9)

Country Link
US (3) US7615228B2 (en)
EP (2) EP1331271B1 (en)
JP (3) JP5681337B2 (en)
KR (2) KR101121754B1 (en)
CN (2) CN101367869B (en)
AU (1) AU2002220460A1 (en)
BR (2) BR0114510A (en)
MX (1) MXPA03002751A (en)
WO (1) WO2002040681A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101367869B (en) * 2000-09-30 2012-12-05 北京万泰生物药业股份有限公司 Polypeptide for preventing, diagnosing and treating hepatitis E virus, and vaccine as diagnosis agent of the same
MXPA04004321A (en) 2001-11-08 2004-08-11 Yang Sheng Tang Co Ltd Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof.
CN1850855B (en) * 2006-05-26 2012-08-29 厦门大学 Method and composition for immuning or preparing monoclonal antibody
WO2010099547A1 (en) * 2009-02-27 2010-09-02 The Regents Of The University Of California Multiple antigen delivery system using hepatitis e virus-like particle
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
CN103168277B (en) * 2010-08-31 2016-06-08 Abb技术有限公司 For debugging the process including multiple subsystem or the method for maker solution
CN102453748A (en) * 2010-10-18 2012-05-16 北京雅康博生物科技有限公司 Plasmid standard substance for fluorescent quantitative PCR quantitative detection
CN102565410B (en) * 2012-01-12 2014-08-06 吉林大学 Immunologic detection method for sika deer prion protein
PL2846829T3 (en) * 2012-05-09 2022-01-24 Bharat Biotech International Limited Vaccine combinations
CN104031144B (en) * 2013-03-05 2017-08-25 厦门大学 Specific bond HEV 3, antibody of 4 types and application thereof
CN104789534B (en) * 2015-04-10 2017-10-17 浙江中医药大学 A kind of hybridoma, monoclonal antibody and application thereof
FR3044312B1 (en) 2015-11-30 2017-12-08 Biomerieux Sa MUTUATED HEV POLYPEPTIDES AND THEIR USE FOR THE ASSAY OF ANTI-HEV ANTIBODIES
WO2017202973A1 (en) * 2016-05-25 2017-11-30 Intervet International B.V. Hev vaccine
KR101924093B1 (en) 2017-04-18 2018-11-30 건국대학교 산학협력단 Primer set for diagnosis of hapatitis E virus genotype 3 and 4 and method for diagnosing the same
CN110501505B (en) * 2018-05-18 2022-06-10 中国兽医药品监察所 Peste des petits ruminants diagnostic kit
JP7454546B2 (en) * 2018-07-10 2024-03-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Antibodies having specificity for the ORF2i protein of hepatitis E virus and their use for diagnostic purposes
WO2020011752A1 (en) * 2018-07-10 2020-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for the orf2i protein of hepatitis e virus and uses thereof for diagnostic purposes
CN109942702B (en) * 2019-03-20 2019-11-08 南京医科大学 A kind of full molecule IgG of people mouse inosculating antibody HEV and its application
JP7259622B2 (en) 2019-07-29 2023-04-18 パナソニックホールディングス株式会社 Cooling system and its operation method
EP4372378A4 (en) * 2021-07-06 2025-01-08 Advanced Life Science Inst Inc METHOD FOR DETECTING HEPATITIS E VIRUS INFECTION AS WELL AS ANTIGEN POLYPEPTIDE AND KIT FOR DETECTING HEPATITIS E VIRUS INFECTION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219515A (en) 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US6214970B1 (en) * 1988-06-17 2001-04-10 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US5885768A (en) 1988-06-17 1999-03-23 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis E virus peptide antigen and antibodies
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
US5563032A (en) * 1992-10-21 1996-10-08 The United States Of America As Represented By The Department Of Health And Human Services Mosaic polypeptide and methods for detecting the hepatitis E virus
WO1995017501A1 (en) 1993-12-22 1995-06-29 Abbott Laboratories Monoclonal antibodies against hev orf-2 and methods for using same
KR100359526B1 (en) * 1994-10-03 2003-02-25 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Recombinant proteins of a pakistani strain of hepatitis e and their in diagnotic methods and vaccines
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
DE19830896A1 (en) * 1998-07-10 2000-06-08 Mivatec Gmbh Photo plot process for high-energy recording of a computer-stored raster image on a light-sensitive recording medium
US6045567A (en) * 1999-02-23 2000-04-04 Lifescan Inc. Lancing device causing reduced pain
CA2283538A1 (en) * 1999-09-30 2001-03-30 Mun Hon Ng New hev antigenic peptide and methods
CN101367869B (en) * 2000-09-30 2012-12-05 北京万泰生物药业股份有限公司 Polypeptide for preventing, diagnosing and treating hepatitis E virus, and vaccine as diagnosis agent of the same

Also Published As

Publication number Publication date
KR101121754B1 (en) 2012-03-23
EP2298793A2 (en) 2011-03-23
US7615228B2 (en) 2009-11-10
EP1331271A4 (en) 2005-04-06
KR100927221B1 (en) 2009-11-16
EP2298793A3 (en) 2011-06-29
CN1345775A (en) 2002-04-24
EP1331271A1 (en) 2003-07-30
MXPA03002751A (en) 2004-05-04
US8524868B2 (en) 2013-09-03
US20100150962A1 (en) 2010-06-17
JP2004525613A (en) 2004-08-26
EP1331271B1 (en) 2014-03-19
US20040052813A1 (en) 2004-03-18
US8715695B2 (en) 2014-05-06
JP2011201881A (en) 2011-10-13
KR20090088429A (en) 2009-08-19
US20100143410A1 (en) 2010-06-10
WO2002040681A1 (en) 2002-05-23
CN101367869B (en) 2012-12-05
JP5829830B2 (en) 2015-12-09
BR0114510A (en) 2004-02-17
JP5681337B2 (en) 2015-03-04
JP2014138593A (en) 2014-07-31
CN101367869A (en) 2009-02-18
BRPI0114510B1 (en) 2019-09-03
BRPI0114510B8 (en) 2021-05-25
KR20030048052A (en) 2003-06-18

Similar Documents

Publication Publication Date Title
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
WO2001034801A3 (en) Recombinant gelatin in vaccines
AU2001277961A1 (en) Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
HUP0103908A3 (en) Novel infulenza virus vaccine composition
AU2002367931A1 (en) Alumina-yttria-zirconium oxide/hafnium oxide materials, and methods of making and using the same
WO2002053703A3 (en) Aav2 vectors and methods
AU2001244675A1 (en) Aids virus vaccine with the use of sendai virus vector
WO2003006616A3 (en) Pseudotyped adeno-associated viruses and uses thereof
AU2002349727A1 (en) Hepatitis E virus monoclonal antibodies or the binding fragments of it and the use thereof
AU3808700A (en) Compositions and methods for recombinant adeno-associated virus production
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
WO1998013500A3 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AU2002333773A1 (en) New hepatitis c virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
AU2002237195A1 (en) Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
AU2002250078A1 (en) Quantitative epstein barr virus pcr rapid assay
AU2002307971A1 (en) Vaccine against the nile fever virus
AU2001240018A1 (en) Adeno-associated viral compositions and methods
AU2002305028A1 (en) West nile virus epitopes and uses thereof
AU2001292667A1 (en) Immunogenic composition of hepatitis c and methods of use thereof
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2002233424A1 (en) Peptides having affinity for the GP120 viral protein and use thereof
AU2756301A (en) Compositions comprising genome segments and methods of using the same
AU2002212049A1 (en) Novel silicone material, its preparation method and the use thereof
AU2001234616A1 (en) Vaccine composition, process and methods